Genprex, Inc. financial data

Symbol
GNPX on Nasdaq
Location
Austin, TX
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 104% % -48%
Return On Equity -877% % -114%
Return On Assets -383% % -42%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2,270,346 shares -73%
Common Stock, Shares, Outstanding 1,004,247 shares -82%
Entity Public Float $4,800,000 USD -90%
Common Stock, Value, Issued $1,004 USD -82%
Weighted Average Number of Shares Outstanding, Basic 760,502 shares 986%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $10,070,832 USD -12%
General and Administrative Expense $6,261,424 USD -45%
Costs and Expenses $16,332,719 USD -28%
Operating Income (Loss) $16,332,719 USD 28%
Net Income (Loss) Attributable to Parent $16,769,203 USD 26%
Earnings Per Share, Basic 57 USD/shares 92%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $1,103,315 USD -26%
Accounts Receivable, after Allowance for Credit Loss, Current $0 USD
Assets, Current $1,715,101 USD -11%
Property, Plant and Equipment, Net $0 USD -100%
Intangible Assets, Net (Excluding Goodwill) $0 USD -100%
Other Assets, Noncurrent $1,847,412 USD -7.1%
Assets $3,562,513 USD -8.8%
Liabilities, Current $2,551,706 USD 14%
Liabilities $2,794,706 USD
Retained Earnings (Accumulated Deficit) $167,238,185 USD -11%
Stockholders' Equity Attributable to Parent $767,807 USD -54%
Liabilities and Equity $3,562,513 USD -8.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,161,425 USD 21%
Net Cash Provided by (Used in) Financing Activities $6,028,103 USD -11%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 1,004,247 shares -82%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,866,678 USD 26%
Deferred Tax Assets, Valuation Allowance $27,624,282 USD 18%
Deferred Tax Assets, Gross $28,161,687 USD 17%
Depreciation $463 USD -95%
Deferred Tax Assets, Operating Loss Carryforwards $20,215,112 USD 20%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $80,967,000 USD -49%
Additional Paid in Capital $168,004,988 USD 10%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $928,276 USD -95%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%